Clinical ink

Managing diabetes just got smarter. GlucoseReady, is Clinical ink's cutting-edge solution designed to revolutionize the patient journey in Cardiometabolic #clinicaltrials GlucoseReady simplifies glucose monitoring with: ? Seamless integration for easy data management. ? Real-time insights for smarter decisions. ? Streamlined workflows to save time and effort. Discover how technology can transform diabetes management for patients and providers alike. ?? Learn more: https://lnkd.in/eHQZT5Xj #DiabetesCare #DigitalHealth #GlucoseMonitoring #HealthcareInnovation

?? Wrapping up Week One at Clinical ink! ?? Here’s what’s impressed me so far: ? Lightning-fast onboarding ? C-suite leaders who truly add value for sponsors ? Major innovations in patient retention & adherence for clinical trials—I'll share more in the coming weeks ? GlucoseReady is changing the game in cardiometabolic studies, offering real-time data and instant insights ???? ? Our small-but-mighty team, means agility and true alignment with sponsor needs Curious about any of the above drop me a DM or check out https://lnkd.in/eCePyWhA Excited to see what week 2 has in store! #ClinicalResearch #PatientEngagement #Innovation #ClinicalTrials

We are pleased to announce the promotion of John Pappadakis to Chief Commercial Officer, and Megan Petrylak, PMP to Chief Operating Officer. Their leadership prepares Clinical ink for future growth underpinned by operational and clinical excellence in clinical trial technology. Read more in our press release. https://lnkd.in/dtu2ANDD

The FDA recently posted their 2024 guidance for conducting clinical trials with decentralized elements.?What has changed, and how does it impact sponsors and vendors??Read our analysis in this article authored by Rinah Yamamoto, David Anderson, Chris Bowen, and Bill Barrasso. https://lnkd.in/ecaspdSQ

Clinical ink’s CEO, Jonathan Goldman, MD MBA, joined Jon Beckstrand, CEO of MasterControl, for the Keynote Session at the MasterControl Masters Summit in Salt Lake City on Tuesday, October 15. Amongst other topics they discussed Clinical ink’s rapid adoption of MasterControl’s eQMS?tools into our Quality Ecosystem and how we’ve used these?tools to achieve our current high levels of quality. Jonathan shared how this approach has achieved results of 100% employee training compliance, a QE rate of less than 0.09 per study, QE approval times of <15 days, and zero critical Quality Events or Audit findings.? In addition, a high degree of Quality and compliance has contributed to Clinical ink’s financial performance with gross margin improvement of >10%.?The discussion included the recent MasterControl product offerings implemented by Clinical ink and how these support our goal of continuous improvement and revenue growth.

We are pleased to report another publication from the WATCH-PD study, in which Clinical ink's Movement Disorder platform was used to remotely monitor Parkinsonian symptoms using a multi-domain collection of sensor and wearable capabilities. In this work, we developed a high-dimensional feature engineering library to construct classification models of PD status. Highlights from this study include: High classification accuracy --> our model predicted PD status with 92% accuracy, 90% sensitivity, and 100% specificity, providing a level of accuracy higher than standard clinical methods in early PD Environment agnostic --> our model was able to predict PD status in both clinic and home environments, allowing for remote home administration with the same level of performance as when completed in clinic Platform agnostic --> our features and models were able to perform well when applied to data from the mPower study, demonstrating applicability across studies and platforms Enormous thanks for our collaborators on this work: Ray Dorsey, Jamie Adams, Melissa Kostrzebski, MS, MBA, Josh Cosman, Tairmae Kangarloo, Joan Severson, Steve Polyak, Ph.D., Shane Johnson, PhD, Michalis Kantartjis, Allen Best, Daniel Jackson Amato, Brian Severson, Anna Revelez, Michael Merickel, Sean Jezewski

Clinical ink is pleased to announce the launch of EDCXtra?, an innovative Electronic Data Capture (EDC) system.?EDCXtra is based on the company’s best in class direct data capture (DDC)/eSource platform, which has evolved over 17 years, and resulted in multiple FDA approvals.?EDCXtra incorporates all existing DDC functionality into a single web-based application which includes Clinical ink’s industry leading electronic Clinical Outcome Assessments (eCOAs) and eConsent solutions, providing a comprehensive, all-in-one GCP compliant platform. ? Read more about EDCXtra in our press release here: https://lnkd.in/ehEKmxi6

Are you attending?the MASH Drug Development Summit?in Boston, September 24-26? Join Clinical ink’s?David Anderson?on Wednesday, September 25 as he presents a comprehensive digital platform used for remotely monitoring MASH/MASLD symptoms, determining risk of non-adherence, and providing personalized interventions to enhance adherence and retention in clinical trials. For more information on how to get MASH/MASLD data, insights, and decisions to your clinical teams faster, please contact?Craig Hatton. https://lnkd.in/eQF_RzUA

We are delighted to welcome our new Chief Medical Officer, Dr. Nicholas Alp, MD PhD FACC.?Dr. Alp brings more than 30 years of clinical research expertise to Clinical ink, and will lead the creation of innovative solutions and commercial strategies for clinical trial technology based on his experience as an interventional cardiologist and clinical trialist. Read the announcement here: https://lnkd.in/eBFijFst

If you missed our Webinar discussing solutions to unmet needs in GLP1 cardiometabolic clinical trials, please check out the recording.